Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HAIC-FOLFOX + camrelizumab + apatinib
- Development stage
- Phase 3
- Lead developer
- Hengrui Therapeutics
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intra-arterial, Intravenous, Oral
01
Overview
HAIC-FOLFOX + camrelizumab + apatinib is a combination regimen used primarily in the treatment of advanced or unresectable hepatocellular carcinoma (HCC) and other liver cancers. The regimen consists of three components: - **HAIC-FOLFOX** (Hepatic Arterial Infusion Chemotherapy with FOLFOX): This involves the direct infusion of a chemotherapy combination—oxaliplatin, fluorouracil (5FU), and folinic acid (leucovorin)—into the hepatic artery, delivering high local concentrations to liver tumors while minimizing systemic toxicity. Oxaliplatin is a platinum-based DNA crosslinker, 5FU is an antimetabolite that inhibits thymidylate synthase, and folinic acid enhances 5FU’s efficacy[2][3][6][7]. - **Camrelizumab**: A monoclonal antibody targeting PD-1 on T cells, acting as an immune checkpoint inhibitor to enhance anti-tumor immune responses. - **Apatinib**: A small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting tumor angiogenesis. This triple therapy combines locoregional chemotherapy with immunotherapy and targeted antiangiogenic therapy. It aims to maximize tumor response rates by attacking cancer through cytotoxicity, immune activation, and inhibition of blood vessel formation[5].
- Other names
- FOLFOX-Camrelizumab-ApatinibInfusional FOLFOX Plus Camrelizumab and Apatinib
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)VEGFR2 (Vascular endothelial growth factor receptor 2)Pt-DNA adduct (DNA-oxaliplatin adduct)
Beyond the preview
Go deeper on HAIC-FOLFOX + camrelizumab + apatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HAIC-FOLFOX + camrelizumab + apatinib.